What a surprising and impressive positive result! Especially since the ganaxolone write-down brings significant headwinds for Q4.
The turnaround after Q3 was in the right direction when it seemed that Nubeqa was selling at a faster pace than previously expected. But I didn’t quite believe in such strong momentum.